In Vitro Antifungal Susceptibility Profile of Miltefosine Against a Collection of Azole and Echinocandins Resistant Fusarium Strains Publisher



Nosratabadi M^{1, 2} ; Akhtari J³ ; Faeli L^{1, 2} ; Haghani I^{1, 2} ; Aghili SR^{1, 2} ; Shokohi T^{1, 2} ; Hedayati MT^{1, 2} ; Zarrinfar H⁴ ; Mohammadi R⁵ ; Najafzadeh MJ⁶ ; Khodavaisy S⁷ ; Alharrasi A⁸ ; Javannikkhah M⁹ ; Kachuei R¹⁰ Show All Authors Show Affiliations
Source: Journal of Fungi Published:2022

Abstract

Fusarium species are filamentous fungi that cause a variety of infections in humans. Because they are commonly resistant to many antifungal drugs currently available in clinical settings, research into alternative targets in fungal cells and therapeutic approaches is required. The antifungal activity of miltefosine and four comparators, amphotericin B, voriconazole, itraconazole, and caspofungin, were tested in vitro against a collection of susceptible and resistant clinical (n = 68) and environmental (n = 42) Fusarium isolates. Amphotericin B (0.8 µg/mL) had the lowest geometric mean (GM) MICs/MECs values followed by miltefosine (1.44 µg/mL), voriconazole (2.15 µg/mL), caspofungin (7.23 µg/mL), and itraconazole (14.19 µg/mL). Miltefosine was the most effective agent against Fusarium isolates after amphotericin B indicating that miltefosine has the potential to be studied as a novel treatment for Fusarium infections. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.